{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:52:25Z","timestamp":1792687945458,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-05014-x","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T02:45:53Z","timestamp":1782355553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic value of the systemic immune-inflammation index in gastrointestinal cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Jiamin","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaibo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0453-3740","authenticated-orcid":false,"given":"Hong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"3","key":"5014_CR1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3322\/caac.21838","volume":"74","author":"N Jokhadze","year":"2024","unstructured":"Jokhadze N, Das A, Dizon DS. Global cancer statistics: A healthy population relies on population health. CA Cancer J Clin. 2024;74(3):224\u20136. https:\/\/doi.org\/10.3322\/caac.21838.","journal-title":"CA Cancer J Clin"},{"issue":"10440","key":"5014_CR2","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/s0140-6736(24)00757-8","volume":"403","author":"Global incidence","year":"2024","unstructured":"Global incidence. prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(24)00757-8.","journal-title":"Lancet"},{"issue":"3","key":"5014_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"5014_CR4","doi-asserted-by":"publisher","first-page":"109373","DOI":"10.4329\/wjr.v17.i8.109373","volume":"17","author":"S Ren","year":"2025","unstructured":"Ren S, Qin B, Daniels MJ, et al. Developing and validating a computed tomography radiomics strategy to predict lymph node metastasis in pancreatic cancer. World J Radiol. 2025;17(8):109373. https:\/\/doi.org\/10.4329\/wjr.v17.i8.109373.","journal-title":"World J Radiol"},{"issue":"26","key":"5014_CR5","doi-asserted-by":"publisher","first-page":"109500","DOI":"10.3748\/wjg.v31.i26.109500","volume":"31","author":"S Ren","year":"2025","unstructured":"Ren S, Song LN, Zhao R, et al. Serum exosomal hsa-let-7f-5p: A potential diagnostic biomarker for metastatic pancreatic cancer detection. World J Gastroenterol. 2025;31(26):109500. https:\/\/doi.org\/10.3748\/wjg.v31.i26.109500.","journal-title":"World J Gastroenterol"},{"issue":"23","key":"5014_CR6","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1200\/jco-24-02030","volume":"43","author":"Y Kawaguchi","year":"2025","unstructured":"Kawaguchi Y, Hasegawa K, Kashiwabara K, et al. Surgery Versus Ablation for Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF-RCT Trial) and a Nonrandomized Prospective Observational Trial (SURF-Cohort Trial). J Clin Oncol. 2025;43(23):2628\u201338. https:\/\/doi.org\/10.1200\/jco-24-02030.","journal-title":"J Clin Oncol"},{"issue":"3","key":"5014_CR7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.annonc.2020.11.004","volume":"32","author":"WO De Steur","year":"2021","unstructured":"De Steur WO, Van Amelsfoort RM, Hartgrink HH, et al. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial. Ann Oncol. 2021;32(3):360\u20137. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.004.","journal-title":"Ann Oncol"},{"issue":"10494","key":"5014_CR8","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/s0140-6736(25)00052-2","volume":"405","author":"R Sundar","year":"2025","unstructured":"Sundar R, Nakayama I, Markar SR, et al. Gastric cancer. Lancet. 2025;405(10494):2087\u2013102. https:\/\/doi.org\/10.1016\/s0140-6736(25)00052-2.","journal-title":"Lancet"},{"issue":"2","key":"5014_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/s1470-2045(17)30006-2","volume":"18","author":"T Hickish","year":"2017","unstructured":"Hickish T, Andre T, Wyrwicz L, et al. MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2017;18(2):192\u2013201. https:\/\/doi.org\/10.1016\/s1470-2045(17)30006-2.","journal-title":"Lancet Oncol"},{"issue":"3","key":"5014_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","volume":"82","author":"P Tabrizian","year":"2025","unstructured":"Tabrizian P, Holzner ML, Ajmera V, et al. Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study. J Hepatol. 2025;82(3):512\u201322. https:\/\/doi.org\/10.1016\/j.jhep.2024.09.003.","journal-title":"J Hepatol"},{"key":"5014_CR11","doi-asserted-by":"publisher","first-page":"217792","DOI":"10.1016\/j.canlet.2025.217792","volume":"626","author":"Z Jin","year":"2025","unstructured":"Jin Z, Zhang C, Shen L, et al. Harnessing exosomes: From tumor immune escape to therapeutic innovation in gastric cancer immunotherapy. Cancer Lett. 2025;626:217792. https:\/\/doi.org\/10.1016\/j.canlet.2025.217792.","journal-title":"Cancer Lett"},{"issue":"14","key":"5014_CR12","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1158\/1078-0432.Ccr-25-0369","volume":"31","author":"M Alsina","year":"2025","unstructured":"Alsina M, Villacampa G, de Andrea C, et al. A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer - The MONEO Study. Clin Cancer Res. 2025;31(14):2890\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-0369.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"5014_CR13","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamaoncol.2025.1646","volume":"11","author":"J Ta\u00efeb","year":"2025","unstructured":"Ta\u00efeb J, Sullo FG, Lecanu A, et al. Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical Trial. JAMA Oncol. 2025;11(8):874\u201382. https:\/\/doi.org\/10.1001\/jamaoncol.2025.1646.","journal-title":"JAMA Oncol"},{"issue":"1","key":"5014_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-024-01578-x","volume":"17","author":"X Chong","year":"2024","unstructured":"Chong X, Madeti Y, Cai J, et al. Recent developments in immunotherapy for gastrointestinal tract cancers. J Hematol Oncol. 2024;17(1):65. https:\/\/doi.org\/10.1186\/s13045-024-01578-x.","journal-title":"J Hematol Oncol"},{"key":"5014_CR15","doi-asserted-by":"publisher","first-page":"1514736","DOI":"10.3389\/fimmu.2025.1514736","volume":"16","author":"J Ni","year":"2025","unstructured":"Ni J, Qi X, Jin C, et al. Efficacy prediction of systemic immune-inflammation index and prognostic nutritional index in breast cancer patients and their variations after neoadjuvant chemotherapy. Front Immunol. 2025;16:1514736. https:\/\/doi.org\/10.3389\/fimmu.2025.1514736.","journal-title":"Front Immunol"},{"issue":"22","key":"5014_CR16","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1182\/bloodadvances.2019031609","volume":"3","author":"CEM Aarts","year":"2019","unstructured":"Aarts CEM, Hiemstra IH, B\u00e9guin EP, et al. Activated neutrophils exert myeloid-derived suppressor cell activity damaging T cells beyond repair. Blood Adv. 2019;3(22):3562\u201374. https:\/\/doi.org\/10.1182\/bloodadvances.2019031609.","journal-title":"Blood Adv"},{"key":"5014_CR17","doi-asserted-by":"publisher","unstructured":"Dwivedi A, Ui Mhaonaigh A, Carroll M, et al. Emergence of dysfunctional neutrophils with a defect in arginase-1 release in severe COVID-19. JCI Insight. 2024;9(17). https:\/\/doi.org\/10.1172\/jci.insight.171659.","DOI":"10.1172\/jci.insight.171659"},{"issue":"1","key":"5014_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ccell.2024.12.004","volume":"43","author":"W Lee","year":"2025","unstructured":"Lee W, Ko SY, Akasaka H, et al. Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10. Cancer Cell. 2025;43(1):69\u201385. https:\/\/doi.org\/10.1016\/j.ccell.2024.12.004.","journal-title":"Cancer Cell"},{"issue":"10","key":"5014_CR19","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3390\/cancers17101689","volume":"17","author":"J Bl\u00fcmke","year":"2025","unstructured":"Bl\u00fcmke J, Schameitat M, Verma A, et al. Innate Immunity and Platelets: Unveiling Their Role in Chronic Pancreatitis and Pancreatic Cancer. Cancers (Basel). 2025;17(10):1689. https:\/\/doi.org\/10.3390\/cancers17101689.","journal-title":"Cancers (Basel)"},{"key":"5014_CR20","doi-asserted-by":"publisher","first-page":"217281","DOI":"10.1016\/j.canlet.2024.217281","volume":"605","author":"DR Plaugher","year":"2024","unstructured":"Plaugher DR, Childress AR, Gosser CM, et al. Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer. Cancer Lett. 2024;605:217281. https:\/\/doi.org\/10.1016\/j.canlet.2024.217281.","journal-title":"Cancer Lett"},{"issue":"1","key":"5014_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40364-024-00722-6","volume":"13","author":"T He","year":"2025","unstructured":"He T, Xu B, Wang LN, et al. The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy. Biomark Res. 2025;13(1):10. https:\/\/doi.org\/10.1186\/s40364-024-00722-6.","journal-title":"Biomark Res"},{"key":"5014_CR22","doi-asserted-by":"publisher","unstructured":"Huang R, Zheng Y, Zou W, et al. Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors. J Immunol Res. 2022;3781109. https:\/\/doi.org\/10.1155\/2022\/3781109.","DOI":"10.1155\/2022\/3781109"},{"key":"5014_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2147\/JIR.S483208","volume":"18","author":"X Huang","year":"2025","unstructured":"Huang X, Peng G, Kong Y, et al. The Prognostic Value of CRP\/Alb Ratio in Predicting Overall Survival for Hepatocellular Carcinoma Treated with Transcatheter Intra-Arterial Therapy Combined with Molecular-Targeted Agents and PD-1\/PD-L1 Inhibitors. J Inflamm Res. 2025;18:203\u201317. https:\/\/doi.org\/10.2147\/JIR.S483208.","journal-title":"J Inflamm Res"},{"issue":"1","key":"5014_CR24","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s12885-023-11064-1","volume":"23","author":"G Jia","year":"2023","unstructured":"Jia G, Qiu L, Zheng H, et al. Nomogram for predicting survival in patients with advanced hepatocellular carcinoma treated with PD-1 inhibitors: incorporating pre-treatment and post-treatment clinical parameters. BMC Cancer. 2023;23(1):556. https:\/\/doi.org\/10.1186\/s12885-023-11064-1.","journal-title":"BMC Cancer"},{"key":"5014_CR25","doi-asserted-by":"publisher","first-page":"1213255","DOI":"10.3389\/fnut.2023.1213255","volume":"10","author":"X Yan","year":"2023","unstructured":"Yan X, Wang J, Mao J, et al. Identification of prognostic nutritional index as a reliable prognostic indicator for advanced lung cancer patients receiving immune checkpoint inhibitors. Front Nutr. 2023;10:1213255. https:\/\/doi.org\/10.3389\/fnut.2023.1213255.","journal-title":"Front Nutr"},{"key":"5014_CR26","doi-asserted-by":"publisher","first-page":"1560241","DOI":"10.3389\/fimmu.2025.1560241","volume":"16","author":"X Zhang","year":"2025","unstructured":"Zhang X, Zhang Y, Zhang J, et al. Immunotherapy of small cell lung cancer based on prognostic nutritional index. Front Immunol. 2025;16:1560241. https:\/\/doi.org\/10.3389\/fimmu.2025.1560241.","journal-title":"Front Immunol"},{"issue":"1","key":"5014_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12876-022-02199-9","volume":"22","author":"P Ding","year":"2022","unstructured":"Ding P, Guo H, Sun C, et al. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study. BMC Gastroenterol. 2022;22(1):121. https:\/\/doi.org\/10.1186\/s12876-022-02199-9.","journal-title":"BMC Gastroenterol"},{"key":"5014_CR28","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.2147\/JIR.S520339","volume":"18","author":"SM Wei","year":"2025","unstructured":"Wei SM, Zeng ZX, Pan RJ, et al. Prognostic Value of the SII-PNI Score in Unresectable HCC Treated with Transcatheter Arterial Chemoembolization Combined with Lenvatinib and PD-1 Inhibitors. J Inflamm Res. 2025;18:7545\u201357. https:\/\/doi.org\/10.2147\/JIR.S520339.","journal-title":"J Inflamm Res"},{"issue":"7","key":"5014_CR29","doi-asserted-by":"publisher","first-page":"106684","DOI":"10.4251\/wjgo.v17.i7.106684","volume":"17","author":"YF Zhu","year":"2025","unstructured":"Zhu YF, Zhang DW, Zhang M, et al. Prognostic value of immune-inflammation and nutritional indices in advanced hepatocellular carcinoma patients receiving immunotherapy with compound Kushen injection. World J Gastrointest Oncol. 2025;17(7):106684. https:\/\/doi.org\/10.4251\/wjgo.v17.i7.106684.","journal-title":"World J Gastrointest Oncol"},{"issue":"9","key":"5014_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135. https:\/\/doi.org\/10.1007\/s10654-010-9491-z.","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"5014_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3892\/ol.2023.14024","volume":"26","author":"C Liu","year":"2023","unstructured":"Liu C, Zhao H, Zhang R, et al. Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors. Oncol Lett. 2023;26(4):437. https:\/\/doi.org\/10.3892\/ol.2023.14024.","journal-title":"Oncol Lett"},{"issue":"3","key":"5014_CR32","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s12094-024-03596-0","volume":"27","author":"Y Yao","year":"2025","unstructured":"Yao Y, Zhang M, Liu D, et al. Changes in systemic immune-inflammation index (SII) predict the prognosis of patients with hepatitis B-related hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors. Clin Transl Oncol. 2025;27(3):1155\u201365. https:\/\/doi.org\/10.1007\/s12094-024-03596-0.","journal-title":"Clin Transl Oncol"},{"key":"5014_CR33","doi-asserted-by":"publisher","first-page":"1496095","DOI":"10.3389\/fimmu.2024.1496095","volume":"15","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Guan R, Zhao R, et al. Prognosis prediction of alpha-FAtE score for locoregional immunotherapy in hepatocellular carcinoma. Front Immunol. 2024;15:1496095. https:\/\/doi.org\/10.3389\/fimmu.2024.1496095.","journal-title":"Front Immunol"},{"key":"5014_CR34","doi-asserted-by":"publisher","first-page":"585271","DOI":"10.3389\/fonc.2021.585271","volume":"11","author":"J Shang","year":"2021","unstructured":"Shang J, Han X, Zha H, et al. Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade. Front Oncol. 2021;11:585271. https:\/\/doi.org\/10.3389\/fonc.2021.585271.","journal-title":"Front Oncol"},{"key":"5014_CR35","doi-asserted-by":"publisher","first-page":"589022","DOI":"10.3389\/fonc.2021.589022","volume":"11","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zhang C, Peng Z, et al. Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor. Front Oncol. 2021;11:589022. https:\/\/doi.org\/10.3389\/fonc.2021.589022.","journal-title":"Front Oncol"},{"issue":"1","key":"5014_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/imm.13759","volume":"172","author":"Q Dong","year":"2024","unstructured":"Dong Q, Zhao F, Li Y, et al. The correlation between systemic inflammatory markers and efficiency for advanced gastric cancer patients treated with ICIs combined with chemotherapy. Immunology. 2024;172(1):77\u201390. https:\/\/doi.org\/10.1111\/imm.13759.","journal-title":"Immunology"},{"issue":"6","key":"5014_CR37","doi-asserted-by":"publisher","first-page":"e007054","DOI":"10.1136\/jitc-2023-007054","volume":"11","author":"M He","year":"2023","unstructured":"He M, Chen ZF, Zhang L, et al. Associations of subcutaneous fat area and Systemic Immune-inflammation Index with survival in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade. J Immunother Cancer. 2023;11(6):e007054. https:\/\/doi.org\/10.1136\/jitc-2023-007054.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"5014_CR38","doi-asserted-by":"publisher","first-page":"25336","DOI":"10.1038\/s41598-025-09707-3","volume":"15","author":"MM Mildanoglu","year":"2025","unstructured":"Mildanoglu MM, Kutlu Y, Bas O, et al. Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS\u2009\u2265\u20095: Turkish Oncology Group (TOG) study. Sci Rep. 2025;15(1):25336. https:\/\/doi.org\/10.1038\/s41598-025-09707-3.","journal-title":"Sci Rep"},{"key":"5014_CR39","doi-asserted-by":"publisher","first-page":"783197","DOI":"10.3389\/fonc.2022.783197","volume":"12","author":"Z Qu","year":"2022","unstructured":"Qu Z, Wang Q, Wang H, et al. The Effect of Inflammatory Markers on the Survival of Advanced Gastric Cancer Patients Who Underwent Anti-Programmed Death 1 Therapy. Front Oncol. 2022;12:783197. https:\/\/doi.org\/10.3389\/fonc.2022.783197.","journal-title":"Front Oncol"},{"issue":"5","key":"5014_CR40","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10120-025-01622-w","volume":"28","author":"LL Shen","year":"2025","unstructured":"Shen LL, Zheng HL, Zheng ZW, et al. Paradoxical effects of adiposity and inflammation on immunotherapy efficacy in gastric cancer: novel insights from real-world data. Gastric Cancer. 2025;28(5):911\u201323. https:\/\/doi.org\/10.1007\/s10120-025-01622-w.","journal-title":"Gastric Cancer"},{"issue":"3","key":"5014_CR41","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.21037\/tcr-2025-192","volume":"14","author":"Y Sun","year":"2025","unstructured":"Sun Y, Yan F, Yu X, et al. Retrospective study on the prognostic prediction of inflammatory markers and the C-reactive protein\/albumin ratio in first-line immunotherapy for advanced HER2 negative gastric cancer patients. Translational Cancer Res. 2025;14(3):2043\u201353. https:\/\/doi.org\/10.21037\/tcr-2025-192.","journal-title":"Translational Cancer Res"},{"key":"5014_CR42","doi-asserted-by":"publisher","first-page":"1029960","DOI":"10.3389\/fonc.2022.1029960","volume":"12","author":"M Wan","year":"2022","unstructured":"Wan M, Ding Y, Mao C, et al. Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment. Front Oncol. 2022;12:1029960. https:\/\/doi.org\/10.3389\/fonc.2022.1029960.","journal-title":"Front Oncol"},{"key":"5014_CR43","doi-asserted-by":"publisher","first-page":"e18659","DOI":"10.7717\/peerj.18659","volume":"12","author":"M Zhu","year":"2024","unstructured":"Zhu M, Zhang LT, Lai W, et al. Prognostic value of inflammatory and nutritional indexes among patients with unresectable advanced gastric cancer receiving immune checkpoint inhibitors combined with chemotherapy-a retrospective study. PeerJ. 2024;12:e18659. https:\/\/doi.org\/10.7717\/peerj.18659.","journal-title":"PeerJ"},{"key":"5014_CR44","doi-asserted-by":"publisher","first-page":"1144875","DOI":"10.3389\/fonc.2023.1144875","volume":"13","author":"L Da","year":"2023","unstructured":"Da L, Qu Z, Zhang C, et al. Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment. Front Oncol. 2023;13:1144875. https:\/\/doi.org\/10.3389\/fonc.2023.1144875.","journal-title":"Front Oncol"},{"issue":"4","key":"5014_CR45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s00262-025-03963-y","volume":"74","author":"L Dong","year":"2025","unstructured":"Dong L, Ma Y, Cao G, et al. An integrated prognosis prediction model based on real-word clinical characteristics for immunotherapy in advanced esophageal squamous cell carcinoma. Cancer Immunol Immunother. 2025;74(4):112. https:\/\/doi.org\/10.1007\/s00262-025-03963-y.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"5014_CR46","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/00365521.2024.2319319","volume":"59","author":"M Fu","year":"2024","unstructured":"Fu M, Li Z, Ma J, et al. Study on the predictive value of pretreatment peripheral blood inflammatory markers regarding immunotherapy in patients with inoperable advanced or locally advanced oesophageal squamous cell carcinoma. Scand J Gastroenterol. 2024;59(6):722\u20139. https:\/\/doi.org\/10.1080\/00365521.2024.2319319.","journal-title":"Scand J Gastroenterol"},{"issue":"17","key":"5014_CR47","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/1759-7714.14898","volume":"14","author":"WX Qi","year":"2023","unstructured":"Qi WX, Wang X, Li C, et al. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort. Thorac Cancer. 2023;14(17):1556\u201366. https:\/\/doi.org\/10.1111\/1759-7714.14898.","journal-title":"Thorac Cancer"},{"issue":"39","key":"5014_CR48","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1080\/14796694.2024.2421151","volume":"20","author":"B Wang","year":"2024","unstructured":"Wang B, Wang Z, Wang K, et al. Inflammatory markers correlate with lymphocytes infiltrating and predict immunotherapy prognosis for esophageal cancer. Future Oncol. 2024;20(39):3267\u201378. https:\/\/doi.org\/10.1080\/14796694.2024.2421151.","journal-title":"Future Oncol"},{"issue":"1","key":"5014_CR49","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s12935-021-02072-x","volume":"21","author":"X Wu","year":"2021","unstructured":"Wu X, Han R, Zhong Y, et al. Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma. Cancer Cell Int. 2021;21(1):356. https:\/\/doi.org\/10.1186\/s12935-021-02072-x.","journal-title":"Cancer Cell Int"},{"key":"5014_CR50","doi-asserted-by":"publisher","unstructured":"Zhang Z, Wang D, Ruan Y, et al. Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma. Therapeutic Adv Med Oncol. 2023;15. https:\/\/doi.org\/10.1177\/17588359231169981.","DOI":"10.1177\/17588359231169981"},{"key":"5014_CR51","doi-asserted-by":"publisher","unstructured":"Gao Z, Shen ZG, Liu JH, et al. Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer. World J Gastroenterol. 2025;31(24). https:\/\/doi.org\/10.3748\/wjg.v31.i24.108298.","DOI":"10.3748\/wjg.v31.i24.108298"},{"issue":"1","key":"5014_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12885-025-13440-5","volume":"25","author":"Y Hamakawa","year":"2025","unstructured":"Hamakawa Y, Hirahara A, Hayashi A, et al. Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors. BMC Cancer. 2025;25(1):17. https:\/\/doi.org\/10.1186\/s12885-025-13440-5.","journal-title":"BMC Cancer"},{"key":"5014_CR53","doi-asserted-by":"publisher","unstructured":"Peker P, Ge\u00e7gel A, \u00d6zkan O, et al. Systemic Immune-Inflammation Index as a Prognostic Marker in Gastric and Gastroesophageal Junction Cancers Receiving Perioperative FLOT Therapy. Med (Kaunas). 2025;61(9). https:\/\/doi.org\/10.3390\/medicina61091614.","DOI":"10.3390\/medicina61091614"},{"issue":"1","key":"5014_CR54","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-024-02004-z","volume":"23","author":"X Huang","year":"2024","unstructured":"Huang X, Nepovimova E, Adam V, et al. Neutrophils in Cancer immunotherapy: friends or foes? Mol Cancer. 2024;23(1):107. https:\/\/doi.org\/10.1186\/s12943-024-02004-z.","journal-title":"Mol Cancer"},{"issue":"3","key":"5014_CR55","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.devcel.2025.01.003","volume":"60","author":"E Tavukcuoglu","year":"2025","unstructured":"Tavukcuoglu E, Esendagli G. IL-8 contributes to functional diversity of tumor-infiltrating neutrophils: A new target for cancer immunotherapy. Dev Cell. 2025;60(3):339\u201341. https:\/\/doi.org\/10.1016\/j.devcel.2025.01.003.","journal-title":"Dev Cell"},{"issue":"1","key":"5014_CR56","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1038\/s41467-024-47516-w","volume":"15","author":"MJ Garcia-Leon","year":"2024","unstructured":"Garcia-Leon MJ, Liboni C, Mittelheisser V, et al. Platelets favor the outgrowth of established metastases. Nat Commun. 2024;15(1):3297. https:\/\/doi.org\/10.1038\/s41467-024-47516-w.","journal-title":"Nat Commun"},{"issue":"3","key":"5014_CR57","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41591-025-03514-z","volume":"31","author":"Democratizing precision oncology with SCORPIO","year":"2025","unstructured":"Democratizing precision oncology with SCORPIO. Nat Med. 2025;31(3):741\u20132. https:\/\/doi.org\/10.1038\/s41591-025-03514-z.","journal-title":"Nat Med"},{"issue":"1","key":"5014_CR58","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, et al. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9(1):274. https:\/\/doi.org\/10.1038\/s41392-024-01979-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"5014_CR59","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1002\/jcp.27373","volume":"234","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Lin S, Yang X, et al. Prognostic value of pretreatment systemic immune-inflammation index in patients with gastrointestinal cancers. J Cell Physiol. 2019;234(5):5555\u201363. https:\/\/doi.org\/10.1002\/jcp.27373.","journal-title":"J Cell Physiol"},{"key":"5014_CR60","doi-asserted-by":"publisher","first-page":"1532343","DOI":"10.3389\/fonc.2025.1532343","volume":"15","author":"G Chen","year":"2025","unstructured":"Chen G, Bao B, Ye Y, et al. Prognostic value of the systemic immune-inflammation index in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol. 2025;15:1532343. https:\/\/doi.org\/10.3389\/fonc.2025.1532343.","journal-title":"Front Oncol"},{"key":"5014_CR61","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12935-020-01308-6","volume":"20","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Sun Y, Zhang Q. Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis. Cancer Cell Int. 2020;20:224. https:\/\/doi.org\/10.1186\/s12935-020-01308-6.","journal-title":"Cancer Cell Int"},{"key":"5014_CR62","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jdin.2025.04.020","volume":"23","author":"CNC Pallares","year":"2025","unstructured":"Pallares CNC, S\u00e1nchez C\u00e1rdenas CD, Guzm\u00e1n ZER, et al. Sensitivity and specificity of the neutrophil-to-lymphocyte ratio for predicting mortality in patients with non-metastatic acral melanoma. JAAD Int. 2025;23:67\u20138. https:\/\/doi.org\/10.1016\/j.jdin.2025.04.020.","journal-title":"JAAD Int"},{"issue":"4","key":"5014_CR63","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3390\/medicina61040707","volume":"61","author":"O \u00d6zkan","year":"2025","unstructured":"\u00d6zkan O, Peker P, Ge\u00e7gel A, et al. Prognostic Value of Preoperative Lymphocyte-to-Monocyte Ratio in Patients with Recurrent Colorectal Cancer. Med (Kaunas). 2025;61(4):707. https:\/\/doi.org\/10.3390\/medicina61040707.","journal-title":"Med (Kaunas)"},{"issue":"1","key":"5014_CR64","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41698-025-01020-6","volume":"9","author":"L Paschold","year":"2025","unstructured":"Paschold L, Schultheiss C, Schmidt-Barbo P, et al. Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer. NPJ Precis Oncol. 2025;9(1):272. https:\/\/doi.org\/10.1038\/s41698-025-01020-6.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"5014_CR65","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13046-019-1192-1","volume":"38","author":"Y Chen","year":"2019","unstructured":"Chen Y, Liu Q, Chen Z, et al. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. J Exp Clin Cancer Res. 2019;38(1):193. https:\/\/doi.org\/10.1186\/s13046-019-1192-1.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"5014_CR66","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2214\/ajr.21.26538","volume":"218","author":"S Sheikhbahaei","year":"2022","unstructured":"Sheikhbahaei S, Marcus CV, Sadaghiani MS, et al. Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From the AJR Special Series on Imaging of Inflammation. AJR Am J Roentgenol. 2022;218(6):940\u201352. https:\/\/doi.org\/10.2214\/ajr.21.26538.","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"5014_CR67","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.2214\/ajr.18.20938","volume":"212","author":"R Thomas","year":"2019","unstructured":"Thomas R, Somarouthu B, Alessandrino F, et al. Atypical Response Patterns in Patients Treated With Nivolumab. AJR Am J Roentgenol. 2019;212(6):1177\u201381. https:\/\/doi.org\/10.2214\/ajr.18.20938.","journal-title":"AJR Am J Roentgenol"},{"key":"5014_CR68","doi-asserted-by":"publisher","first-page":"974087","DOI":"10.3389\/fimmu.2022.974087","volume":"13","author":"A Botticelli","year":"2022","unstructured":"Botticelli A, Pomati G, Cirillo A, et al. The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy. Front Immunol. 2022;13:974087. https:\/\/doi.org\/10.3389\/fimmu.2022.974087.","journal-title":"Front Immunol"},{"issue":"10294","key":"5014_CR69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"12","key":"5014_CR70","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.4254\/wjh.v15.i12.1258","volume":"15","author":"HJ Chen","year":"2023","unstructured":"Chen HJ, Huang TX, Jiang YX, et al. Multifunctional roles of inflammation and its causative factors in primary liver cancer: A literature review. World J Hepatol. 2023;15(12):1258\u201371. https:\/\/doi.org\/10.4254\/wjh.v15.i12.1258.","journal-title":"World J Hepatol"},{"key":"5014_CR71","doi-asserted-by":"publisher","unstructured":"Hibino S, Kawazoe T, Kasahara H, et al. Inflammation-Induced Tumorigenesis and Metastasis. Int J Mol Sci. 2021;22(11). https:\/\/doi.org\/10.3390\/ijms22115421.","DOI":"10.3390\/ijms22115421"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05014-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05014-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05014-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:08:08Z","timestamp":1788908888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-05014-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5014"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-05014-x","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"550"}}